BELLEVILLE, ON, July 23, 2013 /CNW/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today reported that the Superior Court of
Justice - Ontario has rendered its decision with respect to the timing
of a shareholder meeting. In his 30-page ruling, Justice Brown declined
the application by a dissident shareholder group to compel a
shareholder meeting and granted a declaration that the dissidents are
not entitled to proceed with the meeting they called for August 27,
As a result, the Company will proceed with its scheduled shareholder
meeting date of November 5, 2013.
The Company is pleased with this outcome, as it allows the meeting to
proceed in accordance with the normal cycle. This allows shareholders
time to consider the issues associated with a contested Board election
and a proposed sale of the Animal Health business.
The Company plans to provide detailed information about its future
plans, including its proposed Director candidates and details of a
purchase offer for the Animal Health business, in a management
information circular that will be distributed to all shareholders prior
to the November meeting.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE: Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097